Welcome to our dedicated page for Aemetis SEC filings (Ticker: AMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aemetis, Inc. (NASDAQ: AMTX) SEC filings page provides access to the company’s official disclosures as a Delaware corporation listed on the NASDAQ Global Market. Through forms such as 10-K, 10-Q, and 8-K, Aemetis reports details about its renewable natural gas, renewable fuel, and biochemicals operations in California and India, along with its financial condition and material agreements.
Current reports on Form 8-K offer insight into key events, including quarterly earnings releases and significant financing arrangements. For example, Aemetis has filed 8-Ks to furnish press releases covering results for periods ended June 30 and September 30, 2025, and to describe amendments to the Series A Preferred Unit Purchase Agreement for its Aemetis Biogas LLC subsidiary. These filings outline redemption obligations, potential credit agreements, and security interests related to the dairy RNG platform.
Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q to review segment information for California ethanol, dairy renewable natural gas, and India biodiesel operations, as well as risk factors tied to commodity prices, regulatory programs such as LCFS and federal tax credits, and project development. These filings also discuss accumulated deficits, debt levels, and capital investments in projects like the Mechanical Vapor Recompression system and dairy digesters.
In addition, forms related to securities and capital structure provide information on Aemetis’ common stock registered on the NASDAQ Global Market under the symbol AMTX, and on obligations of subsidiaries and guarantors. Where available, Form 4 and related ownership filings can be used to monitor insider transactions by officers, directors, or significant shareholders.
On Stock Titan, AI-powered tools can help summarize lengthy Aemetis filings, highlight key terms in credit agreements, and explain complex tables in earnings releases. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, and 10-Ks for AMTX are quickly reflected, allowing users to review how regulatory disclosures align with the company’s renewable fuels and RNG strategy.
Aemetis, Inc. amended its Certificate of Incorporation to increase authorized capital stock to 205,000,000 shares, including a rise in authorized common stock from 80,000,000 to 140,000,000 shares, following stockholder approval at a special meeting.
Stockholders did not approve a reduction in authorized preferred stock from 65,000,000 to 5,000,000 shares, but did approve a discretionary adjournment proposal. Aemetis also updated the official description of its capital stock and filed a legal opinion covering the legality of up to $210,000,000 of common stock that may be sold from time to time under its existing at‑the‑market offering program.
Aemetis, Inc. reported that its subsidiary Aemetis Biogas LLC entered into an Eleventh Waiver and Amendment to its Series A Preferred Unit Purchase Agreement with Protair-X Technologies Inc. and Third Eye Capital Corporation. The amendment extends the deadline to redeem all outstanding Series A Preferred Units from December 31, 2025 to April 30, 2026 and sets the aggregate redemption price at $114.7 million, which reflects prior payments and a $2 million fee for this amendment. If the units are not redeemed by the new date, Aemetis Biogas LLC would instead enter into a credit agreement with Protair-X and Third Eye Capital, effective May 1, 2026, maturing May 1, 2027, with interest at the greater of 16.0% or the prime rate plus 10.0%, guaranteed by Aemetis, Inc. and several subsidiaries and secured by their assets.
Aemetis, Inc. director Simon Timothy Alan received a grant of 12,000 shares of Common Stock on January 22, 2026 at $1.54 per share. The award was made under the Aemetis Amended and Restated 2019 Stock Plan as compensation for his service on the Board of Directors.
After this equity grant, he beneficially owns 52,632 shares of Aemetis Common Stock in direct form.
Aemetis director John R. Block received a grant of 12,000 shares of Aemetis common stock on 01/22/2026 at a price of $1.54 per share. The shares were granted under the Aemetis, Inc. Amended and Restated 2019 Stock Plan as compensation for his service on the Board of Directors.
After this award, he beneficially owns 46,330 shares of Aemetis common stock in direct form.
Aemetis, Inc. director Barton Francis P reported receiving a grant of 18,000 shares of Common Stock on January 22, 2026. The award was priced at $1.54 per share and was issued as compensation for service on the Board of Directors under the Aemetis, Inc. Amended and Restated 2019 Stock Plan.
Following this equity grant, Barton Francis P beneficially owns 226,518 shares of Aemetis Common Stock in direct ownership.
Aemetis, Inc. director Lydia I. Beebe reported receiving a grant of common stock as board compensation. On 01/22/2026, she was awarded 14,500 shares of Aemetis common stock at $1.54 per share under the company’s Amended and Restated 2019 Stock Plan. Following this grant, she beneficially owns 214,286 common shares, held directly. The transaction reflects routine equity-based compensation for service on the Board of Directors.
Aemetis, Inc. director Naomi Louise Boness reported a stock grant received for board service. On 01/22/2026 she acquired 12,000 shares of Aemetis common stock at $1.54 per share under the Aemetis, Inc. Amended and Restated 2019 Stock Plan, as compensation for serving on the Board of Directors. Following this grant, she beneficially owned 64,643 common shares held directly.
Aemetis, Inc. approved several governance and capital actions. The board’s committee authorized an annual $350,000 guarantee fee to McAfee Capital LLC, wholly owned by Chairman and CEO Eric A. McAfee, for personal guarantees supporting certain credit facilities and debt obligations, continuing the company’s historical practice.
The committee also granted discretionary cash bonuses to key executives, including $200,000 to Mr. McAfee and $125,000 each to three executive vice presidents, with another executive vice president receiving $50,000. Separately, the board authorized a share repurchase program allowing the company to buy back up to $80 million of common stock over time, with purchases made at management’s discretion and no set end date. The company is also holding a special stockholder meeting to vote on charter amendments to change authorized common and preferred share levels.
Aemetis, Inc. filed its Q3 2025 10‑Q, reporting revenue of $59.2 million for the quarter and a net loss of $23.7 million. For the nine months, revenue was $154.3 million with a net loss of $71.7 million.
Quarterly results reflected softer biodiesel sales in India and a near break‑even gross margin, while SG&A was $8.5 million. Interest and financing costs remained heavy, with quarterly interest expense of $11.9 million and total other debt‑related costs of $3.3 million.
As of September 30, 2025, cash and equivalents were $5.6 million ($8.6 million including restricted), total debt was $353.5 million, and the ABGL Series A preferred units liability was $131.0 million. The company recorded $16.4 million net cash provided by financing year‑to‑date and $(2.5) million net cash used in operations. Shares outstanding were 65.0 million as of September 30, 2025, and 65,568,542 as of October 31, 2025.
ABGL’s Series A preferred redemption deadline was extended to December 31, 2025; if not redeemed, a credit agreement effective January 1, 2026 would replace it at an interest rate equal to the greater of prime + 10.0% or 16.0%.
Aemetis (AMTX) reported that it issued an earnings press release for the three and nine months ended September 30, 2025. The release is furnished as Exhibit 99.1 to a Form 8-K under Item 2.02 and Item 7.01, and is posted on the company’s website. The Form 8-K and Exhibit 99.1 are deemed “furnished” rather than “filed” under the Exchange Act and are not incorporated by reference into any registration statement.